Summit's Partner Reports Significant Lung Cancer Survival Benefit; New Colorectal Cancer Data Encouraging
SMMT sits 34% above its 52-week low of $13.83 on elevated volume (2.0× avg).
Summary
Summit Therapeutics reported encouraging Phase II results for ivonescimab in metastatic colorectal cancer, showing a 70.8% objective response rate and 100% disease control rate. This new data expands the drug's potential beyond lung cancer. Separately, partner Akeso's Phase III HARMONi-6 trial for ivonescimab in squamous NSCLC demonstrated a significant overall survival benefit, with a hazard ratio of 0.66. This critical Phase III milestone, which was also reported in a recent 8-K and news, significantly de-risks the drug and points to substantial future revenue potential.
At the time of this announcement, SMMT was trading at $18.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.6B. The 52-week trading range was $13.83 to $30.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.